MIRA INFORM
REPORT
|
Report Date : |
24.06.2011 |
IDENTIFICATION DETAILS
|
Name : |
PHARMACHEMIE B.V. |
|
|
|
|
Registered Office : |
Swensweg 5, 2031GA Haarlem |
|
|
|
|
Country : |
Netherlands |
|
|
|
|
Financials (as on) : |
31.12.2009 |
|
|
|
|
Date of Incorporation : |
15.03.1944 |
|
|
|
|
Com. Reg. No.: |
34016881 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacturer of
pharmaceutical preparations |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
€ 500.000 |
|
Status : |
Good |
|
Payment
Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Netherlands |
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CONTACTINFORMATION
|
Company name |
Pharmachemie
B.V. |
|
Tradename |
Pharmachemie B.V. |
|
|
Teva Pharmachemie |
|
|
Teva Pharmachemie Operations |
|
Address |
Swensweg 5 |
|
|
2031GA Haarlem |
|
|
Netherlands |
|
Mail address |
Postbus 552 |
|
|
2003RN Haarlem |
|
|
Netherlands |
|
Telephone number |
0800-0228400 |
|
Telefax number |
0235147192 |
|
E-mail address |
|
|
Website |
CREDIT LIMIT
|
Credit limit |
A credit of € 500.000 may be
granted |
COMPANY INFORMATION
|
Handelsregisternummer |
34016881 |
|
Registered in |
Chamber of commerce Amsterdam |
|
Act of foundation |
23-12-1959 |
|
Date of constitution |
15-03-1944 |
|
Continuation date |
25-04-1972 |
|
Last change in statutes |
07-01-2005 |
|
Legal form |
Besloten Vennootschap (Limited
Company ) |
|
Place
of constitution |
Haarlem |
|
Capital |
EUR 1.770.750 |
|
Issued capital |
EUR 354.150 |
|
Paid up capital |
EUR 354.150 |
NACE-code Manufacture of
pharmaceutical preparations (2442)
SBI-code Manufacture
of pharmaceutical preparations (212)
Formal objective De import- en export van, de
groothandel in, de fabricage van, en het doen fabriceren
van farmaceutische produkten, grondstoffen en artikelen, alsmede het
verwerven, verlenen en exploiteren van licenties, octrooien, patenten,
handelsmerken en other forms van industriele property owned Het oprichten van,
het deelnemen in, het beheren van, het adviseren van, het controleren van, het
samenwerken met, het voeren van de management over en het verlenen van diensten
aan andere vennnootschappen en companies, alsmede het financieren van andere
vennootschappen en companies
(Import and export, the wholesale, manufacturing,
and making manufacturing
pharmaceutical products, raw materials
and products and the acquisition,
provision and operation licenses, patents, patents,
trademarks and other forms of industrial
property owned Establish,
participate in, managing, advising, monitoring, working with, the conduct of
management and on providing services to other companies and vennnootschappen
and finance companies
and other companies)
COMPANY STRUCTURE
Shareholder Pharmachemie
Holding B.V.
Swensweg 5
2031GA
HAARLEM
Netherlands
KvK:
30142776
Active
since: 19-03-1998
Percentage:
100.00%
Ultimate parent company Teva Pharmaceutical Industries
990004977280
Holding company Pharmachemie Holding B.V.
Swensweg 5
2031GA
HAARLEM
KvK:
30142776
Subsidiary Teva Netherlands B.V.
Swensweg 5
2031GA
HAARLEM
KvK:
34096191
Ivax Farma
B.V. Swensweg 5
2031GA
HAARLEM
KvK:
34193015
Affiliated companies PCH Real estate B.V.
Swensweg 5
2031GA HAARLEM
KvK:
30091675
Farmaver
B.V.
Swensweg 5
2031GA
HAARLEM
KvK:
34088047
B.V.
Pharbita
Swensweg 5
2031GA
HAARLEM
KvK:
35009579
Liability declaration Pharmachemie
Holding B.V. (30142776)
Swensweg
5
2031GA
HAARLEM
Bankers ABN Amro Bankers NV
ING Bankers
NV
MANAGEMENT
Management Teva Pharmaceuticals Europe B.V.
Computerweg 10
3542DR
UTRECHT
Netherlands
KvK:
30110625
Authorization:
Jointly authorized
Position:
Manager
Date
appointed: 03-10-2006
E.G.W.H.
Loof
Emile
Gerardus Wilhelmus Hendr
Authorization:
Jointly authorized
Position:
Manager
Date
appointed: 14-04-2000
Date of
birth: 09-06-1949
H.C. Diekema
Hendrik Cornelis
Authorization:
Limited authorization
Position:
Proxy
Date
appointed: 01-07-2010
Date of
birth: 06-10-1963
M.T.
Prinsen-Fris Maria Theresia
Authorization:
Limited authorization
Position:
Proxy
Date
appointed: 01-07-2010
Date of
birth: 13-02-1967
D. van
Schooten Denise
Authorization:
Limited authorization
Position:
Proxy
Date
appointed: 01-07-2010
Date of
birth: 03-05-1976
PAYMENT INFORMATION
Payment experiences Payments are regular
Payments Based on multiple payment experiences up to €
50.000
Quarter: 3
2010: 51 Average days
Quarter: 4
2010: 63 Average days
Quarter: 1
2011: 46 Average days
Quarter:
2 2011: 47 Average days
|
|
invoices |
current quarter |
2011 Q1 |
2010 Q4 |
2010 Q3 |
|
|
Total |
301 |
100% |
702.184 |
703.467 |
682.222 |
698.557 |
|
Within terms |
154 |
62,3% |
437.610 |
452.197 |
218.805 |
393.849 |
|
Delayed 0 - 30 |
138 |
36,7% |
257.882 |
251.270 |
416.578 |
297.556 |
|
Delayed 31 - 60 |
7 |
1,0% |
6.692 |
|
46.839 |
|
|
Delayed 61 - 90 |
|
|
|
|
|
|
|
Delayed 91 - 120 |
1 |
0,0% |
|
|
|
2.861 |
|
Delayed 120+ days |
1 |
0,0% |
|
|
|
4.291 |
FINANCIAL INFORMATION
Auditor PricewaterhouseCoopers
Auditor's report According to the
auditor, the annual account gives a faithful description of the
size and composition of the company.
Type of publication Consolidated
Annual accounts van Pharmachemie
Holding B.V.
Swensweg
5
2031GA
HAARLEM
KvK:
30142776
Publication Publication
according to obligations by law
|
CORE
FIGURES |
|
|
|
|
BOOKYEAR |
2009 |
2008 |
2007 |
|
Quick ratio |
1,06 |
0,74 |
1,05 |
|
Current ratio |
2,13 |
1,76 |
2,07 |
|
Nett workingcapital / Balance
total |
0,43 |
0,31 |
0,41 |
|
Capital and reserves / Balance
total |
0,32 |
0,21 |
0,16 |
|
Capital and reserves / Fixed
assets |
1,64 |
0,73 |
0,77 |
|
Solvency |
0,47 |
0,28 |
0,19 |
|
Nett workingcapital |
121.476.000 |
75.874.000 |
91.538.000 |
|
Capital and reserves |
90.308.000 |
53.273.000 |
35.978.000 |
|
Change capital and reserves |
69,52% |
48,07% |
153,88% |
|
change short term liabilities |
8,57% |
16,40% |
9,89% |
|
Operating profit |
53.192.000 |
27.042.000 |
34.461.000 |
|
Nett Turnover |
358.108.000 |
262.658.000 |
239.097.000 |
Annual accounts The published financial
information is the consolidated group information.
Last annual accounts 2009
Type of publication Corporate
Turnover 2009:
358.108.000
2008:
262.658.000
2007:
239.097.000
2006:
233.997.000
Gross profit 2009: 37.035.000
2008:
74.175.000
2007:
65.465.000
BALANCE sheet
|
BOOKYEAR |
2009 |
2008 |
2007 |
|
End of bookyear |
31-12-2009 |
31-12-2008 |
31-12-2007 |
|
Intangible assets |
6.625.000 |
7.496.000 |
7.299.000 |
|
Tangible assets |
34.141.000 |
32.583.000 |
26.467.000 |
|
Financial assets |
14.274.000 |
32.984.000 |
12.927.000 |
|
Fixed assets |
55.040.000 |
73.063.000 |
46.693.000 |
|
|
|||
|
Stocks and work in progress |
115.258.000 |
101.327.000 |
87.696.000 |
|
Accounts receivable |
111.578.000 |
73.070.000 |
77.918.000 |
|
Stocks |
314.000 |
|
424.000 |
|
Liquid assets |
2.191.000 |
825.000 |
10.849.000 |
|
Current assets |
229.341.000 |
175.222.000 |
176.887.000 |
|
Total assets |
284.381.000 |
248.285.000 |
223.580.000 |
|
|
|||
|
Capital and reserves |
90.308.000 |
53.273.000 |
35.978.000 |
|
Provisions |
|
1.930.000 |
184.000 |
|
Long term liabilities |
86.208.000 |
93.734.000 |
102.069.000 |
|
Trade debts suppliers |
|
21.305.000 |
14.433.000 |
|
Short term interest yielding
debt |
|
6.535.000 |
|
|
Other short term debts |
|
71.508.000 |
70.916.000 |
|
Total short term debt |
107.865.000 |
99.348.000 |
85.349.000 |
|
Total debt |
194.073.000 |
195.012.000 |
187.602.000 |
|
Total Liabilities |
284.381.000 |
248.285.000 |
223.580.000 |
|
|
|||
|
PROFIT
& LOSS ACCOUNT |
|
|
|
|
BOOKYEAR |
2009 |
2008 |
2007 |
|
Turnover |
|
262.658.000 |
239.097.000 |
|
Nett Turnover |
358.108.000 |
262.658.000 |
239.097.000 |
|
Cost of sales |
250.595.000 |
|
173.632.000 |
|
Gross profit |
107.513.000 |
|
65.465.000 |
|
Depreciation and amortization |
|
|
5.826.000 |
|
Raw materials |
|
188.483.000 |
|
|
Other operating charges |
|
47.133.000 |
25.178.000 |
|
Operating charges |
54.321.000 |
235.616.000 |
204.636.000 |
|
Operating profit |
53.192.000 |
27.042.000 |
34.461.000 |
|
Financial income |
|
453.000 |
390.000 |
|
Financial charges |
|
4.280.000 |
5.620.000 |
|
Financial result |
-3.344.000 |
-3.827.000 |
5.230.000 |
|
Result before taxes |
49.848.000 |
23.215.000 |
29.231.000 |
|
Income taxes |
12.813.000 |
5.920.000 |
7.424.000 |
|
Result after taxes |
37.035.000 |
17.295.000 |
21.807.000 |
|
Nett result |
37.035.000 |
17.295.000 |
21.807.000 |
History
|
Liability statements |
Since 13-03-2008 filed a
declaration of liability by Pharmachemie Holding B.V.. Since 13-03-2008 filed
a withdrawal of declaration of liability by Teva Pharmaceuticals Europe B.V.. |
|
Management |
Since 01-07-2010 is Proxy Denise
van Schooten appointed. Since 01-07-2010 is Proxy Maria Theresia Prinsen-Fris
appointed. Since 01-07-2010 is Proxy Hendrik Cornelis Diekema appointed. |
Company structure
Teva Pharmaceutical Industries
(990004977280)
Teva Pharmaceuticals Europe B.V.
(30110625) UTRECHT
Subsidiary (100%)
Orphahell B.V. (30055729)
UTRECHT
Subsidiary
Teva Pharma B.V. (30099369)
UTRECHT
Subsidiary
Pharmachemie South Africa
B.V. (30133977)
HAARLEM Subsidiary (100%)
Pharmachemie Holding B.V.
(30142776)
HAARLEM
Subsidiary (100%)
PCH Real estate B.V.
(30091675)
HAARLEM
Subsidiary (100%)
Pharmachemie B.V.
(34016881) Haarlem
Subsidiary (100%)
Teva Netherlands B.V.
(34096191)
HAARLEM
Subsidiary (100%)
Ivax Farma B.V. (34193015)
HAARLEM
Subsidiary (100%)
Farmaver B.V. (34088047)
HAARLEM Subsidiary (100%)
B.V. Pharbita (35009579)
HAARLEM Subsidiary (100%)
Teva Medical (30110153)
UTRECHT
Subsidiary
Orchem B.V. (30110155)
UTRECHT
Subsidiary
Asaph Farmaceutische Onderneming B.V. (30117451)
UTRECHT
Subsidiary (100%)
Plus Chemicals B.V. (30145789)
UTRECHT
Subsidiary
Teva Pharmaceuticals Finance
Netherlands B.V. (30175193)
UTRECHT
Subsidiary
Teva Holland I B.V. (30209813)
UTRECHT
Subsidiary
Teva Generics B.V. (30209814)
UTRECHT
Subsidiary (100%)
Teva Gen B.V. (30278504)
UTRECHT
Subsidiary
Coverdale B.V. (33289639)
UTRECHT
Subsidiary
Plantex Chemicals B.V. (30069424)
UTRECHT
Management relation (100%)
Teva Pharmaceutical Activities of
holding companies Cooperatieve UA (30218549)
UTRECHT
Management relation (100%)
Asaph II B.V. (30228167)
UTRECHT
Management relation (100%)
Maancirkel Holding B.V. (33185905)
UTRECHT
Management relation (100%)
Ivax International B.V. (33240314)
UTRECHT
Management relation (100%)
Gatio Investments B.V. (33265351)
UTRECHT
Management relation (100%)
Rakepoll Holding B.V. (33286800)
UTRECHT
Management relation (100%)
Pliva Pharma Holding B.V.
(34148854)
UTRECHT
Management relation (100%)
Pliva Finance B.V. (34148859)
UTRECHT
Subsidiary (100%) IVAX
Pharmaceuticals B.V. (34238257)
UTRECHT
Management relation (100%)
ratiopharm B.V. (39058803)
Management relation (100%)
Holland Pharmaceutical Supply B.V.
(28036413)
HAARLEM
Subsidiary (100%)
ratiopharm
netherlands B.V. (30063629)
HAARLEM
Subsidiary (100%)
Pharmethica
B.V. (39062775)
HAARLEM
Subsidiary (100%)
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.93 |
|
UK Pound |
1 |
Rs.72.09 |
|
Euro |
1 |
Rs.64.21 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.